MXPA02002772A - Virus oncolitico. - Google Patents
Virus oncolitico.Info
- Publication number
- MXPA02002772A MXPA02002772A MXPA02002772A MXPA02002772A MXPA02002772A MX PA02002772 A MXPA02002772 A MX PA02002772A MX PA02002772 A MXPA02002772 A MX PA02002772A MX PA02002772 A MXPA02002772 A MX PA02002772A MX PA02002772 A MXPA02002772 A MX PA02002772A
- Authority
- MX
- Mexico
- Prior art keywords
- virus
- tumor cell
- pkr
- stat1
- oncolytic virus
- Prior art date
Links
- 244000309459 oncolytic virus Species 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 4
- 210000004881 tumor cell Anatomy 0.000 abstract 3
- 102000006381 STAT1 Transcription Factor Human genes 0.000 abstract 2
- 108010044012 STAT1 Transcription Factor Proteins 0.000 abstract 2
- 241000711975 Vesicular stomatitis virus Species 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 241000709664 Picornaviridae Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 244000052637 human pathogen Species 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 230000035899 viability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20251—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39787399A | 1999-09-17 | 1999-09-17 | |
| PCT/US2000/025510 WO2001019380A2 (en) | 1999-09-17 | 2000-09-18 | Oncolytic virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02002772A true MXPA02002772A (es) | 2004-04-02 |
Family
ID=23573018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02002772A MXPA02002772A (es) | 1999-09-17 | 2000-09-18 | Virus oncolitico. |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP1716858B9 (enExample) |
| JP (1) | JP5060694B2 (enExample) |
| CN (1) | CN1289098C (enExample) |
| AT (2) | ATE418341T1 (enExample) |
| AU (1) | AU782402B2 (enExample) |
| CA (1) | CA2386920C (enExample) |
| DE (2) | DE60041210D1 (enExample) |
| ES (2) | ES2260057T3 (enExample) |
| HK (1) | HK1044708B (enExample) |
| IL (2) | IL148621A0 (enExample) |
| MX (1) | MXPA02002772A (enExample) |
| NZ (4) | NZ523805A (enExample) |
| WO (1) | WO2001019380A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| US7306902B2 (en) * | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| US8491884B2 (en) | 2000-05-03 | 2013-07-23 | Oncolytics Biotech Inc. | Virus clearance of neoplastic cells from mixed cellular compositions |
| CA2412493C (en) | 2000-06-26 | 2010-11-09 | Wellstat Biologics Corporation | Purging of cells using viruses |
| US7122182B2 (en) | 2001-05-11 | 2006-10-17 | Wellstat Biologics Corporation | Oncolytic virus therapy |
| AU2008201293B2 (en) * | 2001-07-11 | 2011-08-18 | University Of Miami | Recombinant VSV for the treatment of tumor cells |
| JP2004537305A (ja) * | 2001-07-11 | 2004-12-16 | ユニバーシティー オブ マイアミ | 腫瘍細胞の処置のための組換えｖｓｖ |
| JP2004099584A (ja) | 2002-05-02 | 2004-04-02 | Keio Gijuku | Ｈｓｖを用いた抗腫瘍剤 |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| DK1606411T3 (da) * | 2003-03-27 | 2009-03-30 | Ottawa Health Research Inst | Mutant vesikulær stomatitis-vira og anvendelse deraf |
| CA2568772A1 (en) | 2004-06-01 | 2005-12-15 | San Diego State University Foundation | Expression system based on recombinant vesicular stomatitis virus synthesizing t7 rna polymerase |
| ZA200702269B (en) * | 2004-08-20 | 2008-09-25 | Viralytics Ltd | Methods and compositions for treatment of hematologic cancers |
| WO2006017914A1 (en) | 2004-08-20 | 2006-02-23 | Viralytics Limited | Methods and compositions for treatment of hematologic cancers |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| EP1917351A4 (en) | 2005-08-01 | 2009-12-16 | Univ Technologies Int | ATTENUATED REOVIRUS |
| ES2741138T3 (es) | 2006-09-15 | 2020-02-10 | Childrens Hospital Of Eastern Ontario Res Institute Inc | Rhabdovirus oncolítico de Farmington |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| PE20091104A1 (es) * | 2007-12-21 | 2009-07-18 | Wyeth Corp | Virus de la estomatitis vesicular atenuado modificado geneticamente, composiciones y metodos de uso del mismo |
| US10603351B2 (en) | 2008-08-21 | 2020-03-31 | Turnstone Limited Partnership | Engineered synergistic oncolytic viral symbiosis |
| DE102008050860A1 (de) * | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
| US9707285B2 (en) | 2009-03-16 | 2017-07-18 | Turnstone Limited Partnership | Vaccination methods |
| EP2510088B1 (en) * | 2009-12-10 | 2016-10-05 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| US9951117B2 (en) | 2010-09-02 | 2018-04-24 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
| WO2012031137A2 (en) * | 2010-09-02 | 2012-03-08 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
| ES2627529T3 (es) | 2011-06-08 | 2017-07-28 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Composiciones para tratamiento de glioblastoma |
| WO2013050048A2 (en) | 2011-10-07 | 2013-04-11 | Skau Aps | Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped rna viruses |
| CA2901501C (en) | 2013-02-21 | 2023-03-07 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Vaccine composition |
| EP3906931A3 (en) | 2013-04-10 | 2022-02-23 | iSD Immunotech ApS | Use of immune suppressive domains as medicaments |
| EP3008176B1 (en) | 2013-06-14 | 2019-08-07 | Turnstone Limited Partnership | Compositions and methods for enhancing virus replication |
| EP2826856B9 (en) * | 2013-07-16 | 2016-05-04 | Sia Latima | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof |
| CN107076727B (zh) * | 2014-07-21 | 2019-11-01 | 诺威尔卢斯德克有限公司 | 用于确定患者特定突变的致癌指数的方法和系统 |
| CN105233285B (zh) * | 2015-09-06 | 2018-10-12 | 广州威溶特医药科技有限公司 | Epac直接或间接激动剂与溶瘤病毒的联合应用 |
| CN110636853B (zh) | 2017-05-19 | 2024-10-18 | 佐治亚州立大学研究基金会公司 | 重组溶瘤病毒 |
| US10610583B2 (en) | 2017-08-31 | 2020-04-07 | Regents Of The University Of Minnesota | Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus |
| EP4446337A3 (en) | 2017-09-22 | 2025-01-08 | Centre National de la Recherche Scientifique | Mutated glycoprotein of vesicular stomatitis virus |
| CN110499297B (zh) * | 2019-08-29 | 2021-07-09 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
| WO2022033469A1 (zh) * | 2020-08-14 | 2022-02-17 | 上海行深生物科技有限公司 | 重组溶瘤病毒及其构建方法和用途 |
| US20240299540A1 (en) | 2021-02-05 | 2024-09-12 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| US20240218390A1 (en) | 2021-02-26 | 2024-07-04 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
| US20250101122A1 (en) | 2023-09-25 | 2025-03-27 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
| US12403194B2 (en) | 2023-09-25 | 2025-09-02 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1118403B (de) | 1960-01-27 | 1961-11-30 | Hoechst Ag | Verfahren zur Gewinnung von antitumorwirksamen Sporen |
| GB1069144A (en) | 1963-07-10 | 1967-05-17 | Merck & Co Inc | Method for the treatment of malignant tumors |
| US4806347A (en) | 1985-12-11 | 1989-02-21 | Schering Corporation | Interferon combinations |
| ES2188593T3 (es) * | 1992-03-24 | 2003-07-01 | United Cancer Res Inst | Vacuna que contiene un virus vivo. |
| GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
| US7153510B1 (en) * | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| ATE241994T1 (de) | 1996-01-25 | 2003-06-15 | Univ Glasgow | Hsv-mutant-1716 zur behandlung von mesotheliomen |
| DE69837764T2 (de) * | 1997-07-11 | 2008-01-31 | Yale University, New Haven | Rhabdovirus mit gentechnisch veränderter hülle |
| CA2305269C (en) * | 1997-10-09 | 2012-07-03 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| WO1999032648A1 (en) * | 1997-12-22 | 1999-07-01 | The University Of Tennessee Research Corporation | Recombinant rhabdovirus containing a heterologous fusion protein |
| AU3001799A (en) * | 1998-03-12 | 1999-09-27 | Trustees Of The University Of Pennsylvania, The | Producer cells for replication selective viruses in the treatment of malignancy |
| WO1999064570A1 (en) * | 1998-06-12 | 1999-12-16 | Mount Sinai School Of Medicine Of The City University Of New York | Novel methods and interferon deficient substrates for the propagation of viruses |
| CN1477964A (zh) * | 1999-04-15 | 2004-02-25 | 应用病毒治疗肿瘤 |
-
2000
- 2000-09-18 EP EP05025974A patent/EP1716858B9/en not_active Expired - Lifetime
- 2000-09-18 JP JP2001523012A patent/JP5060694B2/ja not_active Expired - Fee Related
- 2000-09-18 MX MXPA02002772A patent/MXPA02002772A/es active IP Right Grant
- 2000-09-18 CN CNB008158983A patent/CN1289098C/zh not_active Expired - Fee Related
- 2000-09-18 DE DE60041210T patent/DE60041210D1/de not_active Expired - Lifetime
- 2000-09-18 NZ NZ523805A patent/NZ523805A/en not_active IP Right Cessation
- 2000-09-18 AT AT05025974T patent/ATE418341T1/de active
- 2000-09-18 AT AT00965106T patent/ATE319460T1/de active
- 2000-09-18 NZ NZ534306A patent/NZ534306A/en not_active IP Right Cessation
- 2000-09-18 CA CA2386920A patent/CA2386920C/en not_active Expired - Fee Related
- 2000-09-18 EP EP00965106A patent/EP1218019B1/en not_active Expired - Lifetime
- 2000-09-18 AU AU75882/00A patent/AU782402B2/en not_active Ceased
- 2000-09-18 NZ NZ534307A patent/NZ534307A/en not_active IP Right Cessation
- 2000-09-18 WO PCT/US2000/025510 patent/WO2001019380A2/en not_active Ceased
- 2000-09-18 NZ NZ517573A patent/NZ517573A/en not_active IP Right Cessation
- 2000-09-18 ES ES00965106T patent/ES2260057T3/es not_active Expired - Lifetime
- 2000-09-18 ES ES05025974T patent/ES2320239T3/es not_active Expired - Lifetime
- 2000-09-18 IL IL14862100A patent/IL148621A0/xx unknown
- 2000-09-18 HK HK02105578.7A patent/HK1044708B/en not_active IP Right Cessation
- 2000-09-18 DE DE60026554T patent/DE60026554T2/de not_active Expired - Lifetime
-
2002
- 2002-03-11 IL IL148621A patent/IL148621A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ534306A (en) | 2005-12-23 |
| EP1218019A2 (en) | 2002-07-03 |
| AU7588200A (en) | 2001-04-17 |
| IL148621A (en) | 2010-02-17 |
| JP5060694B2 (ja) | 2012-10-31 |
| DE60041210D1 (de) | 2009-02-05 |
| WO2001019380A3 (en) | 2001-11-22 |
| HK1044708B (en) | 2006-10-27 |
| DE60026554T2 (de) | 2006-09-28 |
| WO2001019380A2 (en) | 2001-03-22 |
| CA2386920A1 (en) | 2001-03-22 |
| HK1092713A1 (en) | 2007-02-16 |
| EP1716858A2 (en) | 2006-11-02 |
| JP2004525855A (ja) | 2004-08-26 |
| EP1716858B9 (en) | 2009-08-12 |
| CA2386920C (en) | 2012-01-24 |
| EP1218019B1 (en) | 2006-03-08 |
| NZ523805A (en) | 2004-09-24 |
| NZ534307A (en) | 2005-07-29 |
| CN1496268A (zh) | 2004-05-12 |
| HK1044708A1 (en) | 2002-11-01 |
| ES2320239T3 (es) | 2009-05-20 |
| DE60026554D1 (de) | 2006-05-04 |
| AU782402B2 (en) | 2005-07-28 |
| ATE319460T1 (de) | 2006-03-15 |
| EP1716858B1 (en) | 2008-12-24 |
| CN1289098C (zh) | 2006-12-13 |
| ES2260057T3 (es) | 2006-11-01 |
| NZ517573A (en) | 2004-02-27 |
| EP1716858A3 (en) | 2007-08-15 |
| IL148621A0 (en) | 2002-09-12 |
| ATE418341T1 (de) | 2009-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02002772A (es) | Virus oncolitico. | |
| ATE500808T1 (de) | Onkolytische virustherapie | |
| MY133891A (en) | Polyethylene glycol modified interferon therapy | |
| DK1252323T3 (da) | Virus-stammer til den onkolytiske behandling af cancer | |
| AU1854695A (en) | The use of interferon subtypes in the preparation of medicaments to treat viral infections | |
| DE69333321D1 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
| MY141594A (en) | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES | |
| EP1217891A4 (en) | THERAPEUTIC PROCEDURES AND COMPOSITIONS USING VIRUSES FROM THE RECOMBINANT FAMILY OF THE PARAMYXOVIRIDAE | |
| WO2005007078A3 (en) | Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (sars) | |
| MX20503A (es) | Quimopapaina y procedimiento para purificarla | |
| WO2002032942A3 (en) | Compositions and methods for modulating rsv infection and immunity | |
| BR0109928A (pt) | Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal | |
| YU23993A (sh) | Preparati za tretiranje infekcija i oboljenja izazvanih virusom hepatitisa b | |
| WARFEL et al. | Production and initial characterization of guinea pig interferon | |
| WO2003017943A3 (en) | Therapeutic compositions and methods for treating viral infection | |
| ATE155795T1 (de) | Verwendung von leukoregulin zur behandlung von mit einem envelope-virus infizierten tier | |
| SG165996A1 (en) | Combination therapies with l-fmau for the treatment of hepatitis b virus infection | |
| ATE89569T1 (de) | Haemoglobin mit reduziertem virusrisiko und dessen herstellung. | |
| Eylan et al. | Resistance of aged cells to virus replication | |
| Czarniecki et al. | Disparate response of encephalomyocarditis virus and MM virus to interferon in JLS-V9R cells | |
| DE69932741D1 (de) | Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen | |
| ATE262919T1 (de) | Verwendung von il-11 zur verstärkung der zellvermittelten immunität zur behandlung verschiedener viraler und parasitärer infektionen und krebs | |
| DK1250422T3 (da) | Myeloid-kolonistimulerende faktor og anvendelser deraf | |
| DK0979093T3 (da) | Terapeutisk virusmiddel, hvis udvikling kan standses | |
| UA23352A (uk) | beta- D- ГЛЮКОЗАМОHІЙHА СІЛЬ alРha-БРОМІЗОВАЛЕРІАHОВОЇ КИСЛОТИ, ЯКА МАЄ ПРОТИВІРУСHУ АКТИВHІСТЬ ВІДHОСHО ВІРУСУ ВЕЗИКУЛЯРHОГО СТОМАТИТУ, ВІРУСУ ПРОСТОГО ГЕРПЕСУ ТА КОРОHАВІРУСУ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| HC | Change of company name or juridical status |